Business Context and Reporting Period
This Form 6-K filing by Bionomics Limited (not Neuphoria Therapeutics Inc.) covers the month of May 2022, with a specific reporting date of May 18, 2022. The filing discloses a regulatory requirement under Australian law regarding a change in a director's interest in the company's securities.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of a corporate governance event and contains no financial performance data.
Material Changes
The material change disclosed is a Change in Director's Interest Notice lodged on behalf of director Mr. Peter Miles Winston Davies. This notice was submitted to the Australian Securities Exchange (ASX) on Appendix 3Y to reflect changes in his holdings of the company's securities and contracts.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to transmit the director's interest notice to the SEC.
Investor Verification Checklist
- Verify the specific nature and volume of the securities transaction made by Director Mr. Peter Miles Winston Davies via the attached Exhibit 99.1.
- Confirm the current total shareholding of Mr. Davies post-transaction against the company's latest insider ownership reports.
- Note that this filing contains no financial results; investors should refer to the company's most recent Form 20-F or quarterly reports for financial metrics.